iiinova — where your digital self keeps evolving

Reposted by Molly Beinfeld

CEVR @tuftscevr.bsky.social · 04/08/2025

What explains the wide range of specialty drug rebates? New research from @mollytoba.bsky.social et al finds cancer/orphan drugs have the lowest rebates, and biosimilars/originators the highest. Read more in Health Affairs Scholar at: tinyurl.com/y4rc468d @argenx.com #PBM #Rebates #DrugPrices

tinyurl.com

What drug characteristics explain the wide range of manufacturer rebates?

AbstractIntroduction. Prescription drug list prices, often cited in policy discussions, do not account for rebates negotiated between manufacturers and pay

042

Reposted by Molly Beinfeld

CEVR @tuftscevr.bsky.social · 07/07/2025

1/ How closely do health plans’ drug #utilizationmanagement (UM) policies align with #clinicalguidelines? CEVR and NPC examined policies for 389 drug-indication pairs from 18 commercial insurers. Here’s a thread on what we found:

133

Molly Beinfeld @mollytoba.bsky.social · 05/05/2025

Gearing up for a busy #ISPORAnnual for the @tuftscevr.bsky.social SPEC team! Come say hello, learn about our research and the SPEC database. #heor #marketaccess #healthpolicy

021

Reposted by Molly Beinfeld

CEVR @tuftscevr.bsky.social · 30/04/2025

Come see CEVR's faculty and researchers share their work and insights at #ISPOR2025 in Montreal! A list of our panels, workshops, poster presentations, and other activities can be found at tinyurl.com/mwy8yv3a #ISPOR #HEOR #HealthPolicy

cevr.tuftsmedicalcenter.org

CEVR Participation at ISPOR 2025 - Center for the Evaluation of Value and Risk in Health

021

Molly Beinfeld @mollytoba.bsky.social · 15/04/2025

@tuftscevr.bsky.social Tufts CEVR annual meeting kicking off with an interview of Dariush Mozaffarian @foodismedicine.bsky.social discussing cardiometabolic health

110

Reposted by Molly Beinfeld

CEVR @tuftscevr.bsky.social · 08/04/2025

Cancer drugs' average US net launch prices doubled from $100K to $200K between 2008 and 2022, with no clear link to clinical efficacy, raising questions about whether these prices reflect value. Read new research co-authored by CEVR’s Katherine Clifford and James Chambers: tinyurl.com/4my6h8zs

tinyurl.com

An analysis of US net cancer drug launch prices and clinical efficacy and certainty of evidence from 2008 to 2022

Abstract. Over the last 15 years, cancer drug prices have increased substantially in the United States (US), with question marks on whether this can be jus

022

Reposted by Molly Beinfeld

CEVR @tuftscevr.bsky.social · 07/04/2025

US commercial and Medicare Advantage health plan coverage of anti-VEGF tx is frequently tighter than the FDA label. Plans require step therapy in up to 75% of policies; restrictions more frequent for originator drugs vs. biosimilars. New from CEVR / Impact Education in JMCP: tinyurl.com/ydd783e4

tinyurl.com

Assessing variation in US payer coverage of anti–vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema | ...

BACKGROUND: Timely anti–vascular endothelial growth factor (anti-VEGF) therapy is recommended to preserve vision in age-related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macu...

011

Reposted by Molly Beinfeld

Mark Cuban @mcuban.bsky.social · 22/03/2025

From 2010 to 2016 (latest data I have ), NIH research contributed to EVERY drug approved by the FDA

708319728473

Reposted by Molly Beinfeld

CEVR @tuftscevr.bsky.social · 07/03/2025

The National Eczema Association awarded a Spotlight Research Grant to our #SPEC team to analyze US payer coverage policies for #atopicdermatitis tx. We will study coverage changes due to new evidence, tx, clinical guidelines; how disparities can cause health inequities. tinyurl.com/33sbsdre

tinyurl.com

221

Molly Beinfeld @mollytoba.bsky.social · 06/03/2025

A great study led by my colleague Dan Enright highlighting the power of SPEC data. No only do we track coverage but also the evidence cited in coverage policies, enabling deeper insights into health plan decision making.

010

Reposted by Molly Beinfeld

Peter Neumann @peterneumann11.bsky.social · 04/03/2025

New study by my @tuftscevr.bsky.social colleague, Yolanda Zhu and colleagues. The #IRA #Medicare Part D benefit redesign may significantly lower OOP drug spending for beneficiaries with #dementia and comorbidities. tinyurl.com/5n8uxam3 #IRA #drugs

051

Molly Beinfeld @mollytoba.bsky.social · 03/03/2025

Grateful to Youth Enrichment Services Boston for the amazing ski experience for my tween! Let’s work to make skiing more accessible to all!

010

Reposted by Molly Beinfeld

CEVR @tuftscevr.bsky.social · 03/03/2025

Don't miss an opportunity to work with our renowned faculty! Applications for our 2025 CEA Registry Summer Fellowship close March 17th. Learn more / apply today: cevr.tuftsmedicalcenter.org/news/2025-ce... #internships #fellowship #healthecon @peterneumann11.bsky.social @pattysynnott.bsky.social

cevr.tuftsmedicalcenter.org

2025 CEA Registry Remote Fellowship - Center for the Evaluation of Value and Risk in Health

023